Clinigen has delivered strong underlying growth and reports the integration of IDIS to be on track. Another acquisition today will further drive penetration into Asia, Africa and Australasia. It is expected to be immediately earnings enhancing and looks to fit in well with Clinigen’s strategy to establish a global footprint for its Managed Access and Global Access divisions, supplying unlicensed medicines to patients with an unmet clinical need.
